Satoshi Goto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Satoshi Goto has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Ryoma Morigaki
Department of Neurosurgery, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
8 shared publications - Ryuji Kaji
Tokushima University Graduate School of Medicine, Tokushima, Japan
4 shared publications Masatoshi Ogawa
Dept Neurbiol Therapeu, Inst Biomed Sci, Grad Sch Pharmaceu Sci, Tokushima Univ
3 shared publicationsRyosuke Tsuji
Dept Neurbiol Therapeu, Inst Biomed Sci, Grad Sch Pharmaceu Sci, Tokushima Univ
3 shared publications- Shinichi Matsumoto
Department of Neurology, Osaka Neurological Institute, 2-6-23, Osaka 561-0836, Japan
3 shared publications Hideki Shimazu
Department of Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya, Japan
2 shared publications
Latest Publications
- Open Access
- 31 January 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (1) , 90-93
Writer’s Cramp, a Task-Specific Focal Hand Dystonia, is Treatable With Dopaminergic Modulation Targeting Striatal Striosomes: A Case Report
Writer’s cramp, a task-specific focal hand dystonia, is treatable with dopaminergic modulation targeting striatal striosomes: a case report
- 31 January 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (1) , 90-93
Open AccessWriter’s Cramp, a Task-Specific Focal Hand Dystonia, is Treatable With Dopaminergic Modulation Targeting Striatal Striosomes: A Case Report
Writer’s cramp, a task-specific focal hand dystonia, is treatable with dopaminergic modulation targeting striatal striosomes: a case report
- 26 October 2025
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 13 (6) , 446-449
Clinical Evidence of Senile Choreo‐Athetosis Following Valproate Withdrawal: A Case Report
An 81‐year‐old man with a 30‐year history of taking sodium valproate (800 mg/day) for epilepsy experienced an acute onset of involuntary hyperkinetic movements. This progressive condition kept him bedridden for 3 months before he visited our hospital. Upon admission, he exhibited generalized choreiform and athetotic movements and senile hearing loss. Both brain MRI and CT scans revealed no acute or chronic specific lesions. Notably, his valproate serum concentration was 8.0 mg/L, markedly below the therapeutic range of 50–100 mg/L. Since the COVID‐19 pandemic began, he has limitedly visited his primary care physician for medication refills. No epileptiform activity was identified on the electroencephalography. Given the potential link between his choreo‐athetosis and withdrawal of chronic valproate treatment, which can act as a D 2 antagonist, he was started on 50 mg of tiapride hydrochloride (a D 2 antagonist) taken thrice daily, which significantly improved his choreo‐athetosis within a week.
- 26 October 2025
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 13 (6) , 446-449
Clinical Evidence of Senile Choreo‐Athetosis Following Valproate Withdrawal: A Case Report
An 81‐year‐old man with a 30‐year history of taking sodium valproate (800 mg/day) for epilepsy experienced an acute onset of involuntary hyperkinetic movements. This progressive condition kept him bedridden for 3 months before he visited our hospital. Upon admission, he exhibited generalized choreiform and athetotic movements and senile hearing loss. Both brain MRI and CT scans revealed no acute or chronic specific lesions. Notably, his valproate serum concentration was 8.0 mg/L, markedly below the therapeutic range of 50–100 mg/L. Since the COVID‐19 pandemic began, he has limitedly visited his primary care physician for medication refills. No epileptiform activity was identified on the electroencephalography. Given the potential link between his choreo‐athetosis and withdrawal of chronic valproate treatment, which can act as a D 2 antagonist, he was started on 50 mg of tiapride hydrochloride (a D 2 antagonist) taken thrice daily, which significantly improved his choreo‐athetosis within a week.
- Open Access
- 20 August 2025
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 19, 1621054
Therapeutic effects of striatal dopaminergic modulation on idiopathic dystonia and OCD in humans: insights from the striosome hypothesis
Emerging evidence suggests that striatal striosomes play a key role in the dopaminergic regulation of motor and mental action selection processes, with impairments leading to repetitive stereotyped movements (dystonias), thoughts (obsessions), and behaviors (compulsions). To explore this hypothesis therapeutically, we investigated how idiopathic dystonia and obsessive-compulsive disorder (OCD) respond to a novel dopaminergic treatment using low-dose L-DOPA combined with chlorpromazine (CPZ), which can primarily enhance striosomal D1 dopamine receptor (D1R) signaling in humans. The therapeutic effects of L-DOPA/CPZ were assessed over 1 year in 26 idiopathic dystonia patients (mean age, 55.9 years; 23.1% male) with OCD. The daily doses of L-DOPA/carbidopa and CPZ-phenolphthalinate were increased stepwise to 50 mg and 5 mg, respectively, three times daily over an 8-weeks period, and then maintained for a year. The severity of dystonia and OCD was evaluated using the Burke-Fahn-Marsden Dystonia Movement Scale (BFMDMS) and Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). At a 1-year follow-up, the BFMDMS and Y-BOCS scores improved by approximately 80% (mean difference, −13.8; 95% CI, −16.9 to −10.6; P < 0.0001) and 75% (mean difference, −16.0; 95% CI, −16.1 to −15.8; P < 0.0001), respectively, with no specific adverse effects. Thus, low-dose L-DOPA/CPZ provided striking and lasting benefits to patients with idiopathic dystonia and OCD. Our findings indicate that dystonia and OCD may share a common striatal dysfunction due to altered D1R signaling in the striosomes. Pharmacologic interventions aimed at modulating striosomal D1R signaling could enhance our understanding of the striatal mechanisms involved in the pathophysiology of both dystonia and OCD.
- 20 August 2025
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 19, 1621054
Open AccessTherapeutic effects of striatal dopaminergic modulation on idiopathic dystonia and OCD in humans: insights from the striosome hypothesis
Emerging evidence suggests that striatal striosomes play a key role in the dopaminergic regulation of motor and mental action selection processes, with impairments leading to repetitive stereotyped movements (dystonias), thoughts (obsessions), and behaviors (compulsions). To explore this hypothesis therapeutically, we investigated how idiopathic dystonia and obsessive-compulsive disorder (OCD) respond to a novel dopaminergic treatment using low-dose L-DOPA combined with chlorpromazine (CPZ), which can primarily enhance striosomal D1 dopamine receptor (D1R) signaling in humans. The therapeutic effects of L-DOPA/CPZ were assessed over 1 year in 26 idiopathic dystonia patients (mean age, 55.9 years; 23.1% male) with OCD. The daily doses of L-DOPA/carbidopa and CPZ-phenolphthalinate were increased stepwise to 50 mg and 5 mg, respectively, three times daily over an 8-weeks period, and then maintained for a year. The severity of dystonia and OCD was evaluated using the Burke-Fahn-Marsden Dystonia Movement Scale (BFMDMS) and Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). At a 1-year follow-up, the BFMDMS and Y-BOCS scores improved by approximately 80% (mean difference, −13.8; 95% CI, −16.9 to −10.6; P < 0.0001) and 75% (mean difference, −16.0; 95% CI, −16.1 to −15.8; P < 0.0001), respectively, with no specific adverse effects. Thus, low-dose L-DOPA/CPZ provided striking and lasting benefits to patients with idiopathic dystonia and OCD. Our findings indicate that dystonia and OCD may share a common striatal dysfunction due to altered D1R signaling in the striosomes. Pharmacologic interventions aimed at modulating striosomal D1R signaling could enhance our understanding of the striatal mechanisms involved in the pathophysiology of both dystonia and OCD.
- Open Access
- 31 January 2025
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 18 (1) , 103-105
Complete Relief of Tardive Truncal Dystonia With a Low Dose of Levodopa/Carbidopa: A Case Report
Complete relief of tardive truncal dystonia with a low dose of levodopa/carbidopa: A case report
- 31 January 2025
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 18 (1) , 103-105
Open AccessComplete Relief of Tardive Truncal Dystonia With a Low Dose of Levodopa/Carbidopa: A Case Report
Complete relief of tardive truncal dystonia with a low dose of levodopa/carbidopa: A case report
- 3 December 2024
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (2) , 177-183
Functional pathology of neuroleptic-induced dystonia based on the striatal striosome-matrix dopamine system in humans
Neuroleptic-induced dystonia is a source of great concern in clinical practice because of its iatrogenic nature which can potentially lead to life-threatening conditions. Since all neuroleptics (antipsychotics) share the ability to block the dopamine D2-type receptors (D2Rs) that are highly enriched in the striatum, this drug-induced dystonia is thought to be caused by decreased striatal D2R activity. However, how associations of striatal D2R inactivation with dystonia are formed remains elusive.A growing body of evidence suggests that imbalanced activities between D1R-expressing medium spiny neurons and D2R-expressing medium spiny neurons (D1-MSNs and D2-MSNs) in the striatal striosome-matrix system underlie the pathophysiology of various basal ganglia disorders including dystonia. Given the specificity of the striatal dopamine D1system in ‘humans’, this article highlights the striatal striosome hypothesis in causing ‘repetitive’ and ‘stereotyped’ motor symptoms which are key clinical features of dystonia. It is suggested that exposure to neuroleptics may reduce striosomal D1-MSN activity and thereby cause dystonia symptoms. This may occur through an increase in the striatal cholinergic activity and the collateral inhibitory action of D2-MSNs onto neighbouring D1-MSNs within the striosome subfields. The article proposes a functional pathology of the striosome-matrix dopamine system for neuroleptic-induced acute dystonia or neuroleptic-withdrawal dystonia. A rationale for the effectiveness of dopaminergic or cholinergic pharmacotherapy is also provided for treating dystonias. This narrative review covers various aspects of the relevant field and provides a detailed discussion of the mechanisms of neuroleptic-induced dystonia.
- 3 December 2024
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (2) , 177-183
Functional pathology of neuroleptic-induced dystonia based on the striatal striosome-matrix dopamine system in humans
Neuroleptic-induced dystonia is a source of great concern in clinical practice because of its iatrogenic nature which can potentially lead to life-threatening conditions. Since all neuroleptics (antipsychotics) share the ability to block the dopamine D2-type receptors (D2Rs) that are highly enriched in the striatum, this drug-induced dystonia is thought to be caused by decreased striatal D2R activity. However, how associations of striatal D2R inactivation with dystonia are formed remains elusive.A growing body of evidence suggests that imbalanced activities between D1R-expressing medium spiny neurons and D2R-expressing medium spiny neurons (D1-MSNs and D2-MSNs) in the striatal striosome-matrix system underlie the pathophysiology of various basal ganglia disorders including dystonia. Given the specificity of the striatal dopamine D1system in ‘humans’, this article highlights the striatal striosome hypothesis in causing ‘repetitive’ and ‘stereotyped’ motor symptoms which are key clinical features of dystonia. It is suggested that exposure to neuroleptics may reduce striosomal D1-MSN activity and thereby cause dystonia symptoms. This may occur through an increase in the striatal cholinergic activity and the collateral inhibitory action of D2-MSNs onto neighbouring D1-MSNs within the striosome subfields. The article proposes a functional pathology of the striosome-matrix dopamine system for neuroleptic-induced acute dystonia or neuroleptic-withdrawal dystonia. A rationale for the effectiveness of dopaminergic or cholinergic pharmacotherapy is also provided for treating dystonias. This narrative review covers various aspects of the relevant field and provides a detailed discussion of the mechanisms of neuroleptic-induced dystonia.
- Open Access
- 30 April 2024
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 17 (2) , 233-235
Meige Syndrome as a Craniofacial Type of Dystonia Treatable by Dual Dopaminergic Modulation Using L-DOPA/Chlorpromazine: A Case Report
- 30 April 2024
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 17 (2) , 233-235
Open AccessMeige Syndrome as a Craniofacial Type of Dystonia Treatable by Dual Dopaminergic Modulation Using L-DOPA/Chlorpromazine: A Case Report
- 1 April 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (2) , e200254
Therapeutic Effects of Dual Dopaminergic Modulation With l -DOPA and Chlorpromazine in Patients With Idiopathic Cervical Dystonia
Imbalanced activities between dopamine D1 and D2 signals in striatal striosome-matrix system have been proposed as a cause of dystonia symptoms. The aim of this study was to assess the therapeutic effects of dual dopaminergic modulation (DDM) with l-DOPA and chlorpromazine (CPZ) in patients with idiopathic cervical dystonia (CD). We enrolled 21 patients with CD who responded poorly to botulinum toxin treatment. The severities of CD motor symptoms and CD-associated pain were determined using the Toronto Western Spasmodic Torticollis Rating Scale and the visual analog scale, respectively. In patients with CD (n = 7), oral administration of l-DOPA combined with CPZ significantly attenuated both CD motor symptoms and CD-associated pain in a dose-related manner. By contrast, there was no improvement of CD symptoms in patients (n = 7) who ingested l-DOPA alone nor in those (n = 7) who ingested CPZ alone. DDM with l-DOPA and CPZ may be an effective tool to treat dystonia symptoms in patients with botulinum toxin-resistant idiopathic CD. Our results may also indicate that CD dystonia symptoms could be attenuated through DDM inducing an increase in striosomal D1-signaling. This study provides Class III evidence that treatment of botulinum toxin-resistant idiopathic cervical dystonia with l-DOPA and chlorpromazine is superior to either one alone.
- 1 April 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (2) , e200254
Therapeutic Effects of Dual Dopaminergic Modulation With l -DOPA and Chlorpromazine in Patients With Idiopathic Cervical Dystonia
Imbalanced activities between dopamine D1 and D2 signals in striatal striosome-matrix system have been proposed as a cause of dystonia symptoms. The aim of this study was to assess the therapeutic effects of dual dopaminergic modulation (DDM) with l-DOPA and chlorpromazine (CPZ) in patients with idiopathic cervical dystonia (CD). We enrolled 21 patients with CD who responded poorly to botulinum toxin treatment. The severities of CD motor symptoms and CD-associated pain were determined using the Toronto Western Spasmodic Torticollis Rating Scale and the visual analog scale, respectively. In patients with CD (n = 7), oral administration of l-DOPA combined with CPZ significantly attenuated both CD motor symptoms and CD-associated pain in a dose-related manner. By contrast, there was no improvement of CD symptoms in patients (n = 7) who ingested l-DOPA alone nor in those (n = 7) who ingested CPZ alone. DDM with l-DOPA and CPZ may be an effective tool to treat dystonia symptoms in patients with botulinum toxin-resistant idiopathic CD. Our results may also indicate that CD dystonia symptoms could be attenuated through DDM inducing an increase in striosomal D1-signaling. This study provides Class III evidence that treatment of botulinum toxin-resistant idiopathic cervical dystonia with l-DOPA and chlorpromazine is superior to either one alone.
- Open Access
- 26 April 2023
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 17
Specificity of striatal dopamine D1 system in humans: implications for clinical use of D1 receptor-agonists in Parkinson's disease
Specificity of striatal dopamine D1 system in humans: implications for clinical use of D1 receptor-agonists in Parkinson's disease
- 26 April 2023
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 17
Open AccessSpecificity of striatal dopamine D1 system in humans: implications for clinical use of D1 receptor-agonists in Parkinson's disease
Specificity of striatal dopamine D1 system in humans: implications for clinical use of D1 receptor-agonists in Parkinson's disease
- Open Access
- 25 July 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13
A dual dopaminergic therapy with L-3,4-dihydroxyphenylalanine and chlorpromazine for the treatment of blepharospasm, a focal dystonia: Possible implications for striosomal D1 signaling
Impairment of balanced activity between dopamine D1 and D2 receptor functions in the striatum, particularly in striatal functional subdivisions (i.e., striosome and matrix compartments), has been proposed to underlie dystonia genesis. This study was undertaken to examine the therapeutic effect of dual dopaminergic modulation with L-3,4-dihydroxyphenylalanine (L-DOPA) and chlorpromazine (CPZ) in patients with blepharospasm, a focal dystonia. For this purpose, Dopacol tablets™ (L-DOPA 50 mg plus carbidopa 5 mg) and Wintermin™ (CPZ phenolphthalinate 180 mg/g) were used. Clinical evaluations were performed before and after an 8-week drug treatment interval using the Visual Analog Scale (VAS), Blepharospasm Disability Index (BSDI), modified VAS (mVAS), and Jankovic Rating Scale (JRS). The data were analyzed using non-parametric statistics. Results showed that in patients (n = 7) with blepharospasm, dystonia symptoms were significantly alleviated by the administration of both Dopacol tablets™ (one tablet × 3/day) and CPZ (5 mg × 3/day), as determined using the VAS, BSDI, mVAS, and JRS. In contrast, there was no improvement of dystonia symptoms in patients (n = 7) who ingested Dopacol tablets™ (one tablet × 3/day) alone, nor in those (n = 7) who ingested CPZ (5 mg × 3/day) alone. Thus, dual pharmacotherapy with L-DOPA and CPZ can exert a therapeutic effect on blepharospasm, suggesting that dystonia symptoms can be attenuated through dopaminergic modulation with inducing an increase in striatal D1-signals. Since dopamine D1 receptors are heavily enriched in the striosome compartment in the “human” striatum, our results also suggest that striosomal loss of D1-signaling may be important in the pathogenesis of dystonia.
- 25 July 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13
Open AccessA dual dopaminergic therapy with L-3,4-dihydroxyphenylalanine and chlorpromazine for the treatment of blepharospasm, a focal dystonia: Possible implications for striosomal D1 signaling
Impairment of balanced activity between dopamine D1 and D2 receptor functions in the striatum, particularly in striatal functional subdivisions (i.e., striosome and matrix compartments), has been proposed to underlie dystonia genesis. This study was undertaken to examine the therapeutic effect of dual dopaminergic modulation with L-3,4-dihydroxyphenylalanine (L-DOPA) and chlorpromazine (CPZ) in patients with blepharospasm, a focal dystonia. For this purpose, Dopacol tablets™ (L-DOPA 50 mg plus carbidopa 5 mg) and Wintermin™ (CPZ phenolphthalinate 180 mg/g) were used. Clinical evaluations were performed before and after an 8-week drug treatment interval using the Visual Analog Scale (VAS), Blepharospasm Disability Index (BSDI), modified VAS (mVAS), and Jankovic Rating Scale (JRS). The data were analyzed using non-parametric statistics. Results showed that in patients (n = 7) with blepharospasm, dystonia symptoms were significantly alleviated by the administration of both Dopacol tablets™ (one tablet × 3/day) and CPZ (5 mg × 3/day), as determined using the VAS, BSDI, mVAS, and JRS. In contrast, there was no improvement of dystonia symptoms in patients (n = 7) who ingested Dopacol tablets™ (one tablet × 3/day) alone, nor in those (n = 7) who ingested CPZ (5 mg × 3/day) alone. Thus, dual pharmacotherapy with L-DOPA and CPZ can exert a therapeutic effect on blepharospasm, suggesting that dystonia symptoms can be attenuated through dopaminergic modulation with inducing an increase in striatal D1-signals. Since dopamine D1 receptors are heavily enriched in the striosome compartment in the “human” striatum, our results also suggest that striosomal loss of D1-signaling may be important in the pathogenesis of dystonia.
- Open Access
Long-Term Follow-Up of 12 Patients Treated with Bilateral Pallidal Stimulation for Tardive Dystonia
Tardive dystonia (TD) is a side effect of prolonged dopamine receptor antagonist intake. TD can be a chronic disabling movement disorder despite medical treatment. We previously demonstrated successful outcomes in six patients with TD using deep brain stimulation (DBS); however, more patients are needed to better understand the efficacy of DBS for treating TD. We assessed the outcomes of 12 patients with TD who underwent globus pallidus internus (GPi) DBS by extending the follow-up period of previously reported patients and enrolling six additional patients. All patients were refractory to pharmacotherapy and were referred for surgical intervention by movement disorder neurologists. In all patients, DBS electrodes were implanted bilaterally within the GPi under general anesthesia. The mean ages at TD onset and surgery were 39.2 ± 12.3 years and 44.6 ± 12.3 years, respectively. The Burke–Fahn–Marsden Dystonia Rating Scale (BFMDRS) performed the preoperative and postoperative evaluations. The average BFMDRS improvement rate at 1 month postoperatively was 75.6 ± 27.6% (p < 0.001). Ten patients were assessed in the long term (78.0 ± 50.4 months after surgery), and the long-term BFMDRS improvement was 78.0 ± 20.4%. Two patients responded poorly to DBS. Both had a longer duration from TD onset to surgery and older age at surgery. A cognitive and psychiatric decline was observed in the oldest patients, while no such decline ware observed in the younger patients. In most patients with TD, GPi-DBS could be a beneficial therapeutic option for long-term relief of TD.
Open AccessLong-Term Follow-Up of 12 Patients Treated with Bilateral Pallidal Stimulation for Tardive Dystonia
Tardive dystonia (TD) is a side effect of prolonged dopamine receptor antagonist intake. TD can be a chronic disabling movement disorder despite medical treatment. We previously demonstrated successful outcomes in six patients with TD using deep brain stimulation (DBS); however, more patients are needed to better understand the efficacy of DBS for treating TD. We assessed the outcomes of 12 patients with TD who underwent globus pallidus internus (GPi) DBS by extending the follow-up period of previously reported patients and enrolling six additional patients. All patients were refractory to pharmacotherapy and were referred for surgical intervention by movement disorder neurologists. In all patients, DBS electrodes were implanted bilaterally within the GPi under general anesthesia. The mean ages at TD onset and surgery were 39.2 ± 12.3 years and 44.6 ± 12.3 years, respectively. The Burke–Fahn–Marsden Dystonia Rating Scale (BFMDRS) performed the preoperative and postoperative evaluations. The average BFMDRS improvement rate at 1 month postoperatively was 75.6 ± 27.6% (p < 0.001). Ten patients were assessed in the long term (78.0 ± 50.4 months after surgery), and the long-term BFMDRS improvement was 78.0 ± 20.4%. Two patients responded poorly to DBS. Both had a longer duration from TD onset to surgery and older age at surgery. A cognitive and psychiatric decline was observed in the oldest patients, while no such decline ware observed in the younger patients. In most patients with TD, GPi-DBS could be a beneficial therapeutic option for long-term relief of TD.